MYRIAD GENETICS, INC. Peo Actually Paid Comp Amt
MYRIAD GENETICS, INC. (MYGN) reported Peo Actually Paid Comp Amt of $7.21 million for the 12-month period ending 2024-12-31, per its DEF 14A filed 2026-04-14.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:PeoActuallyPaidCompAmt · last filed 2026-04-14
| Period end | Peo Actually Paid Comp Amt 12 month |
|---|---|
| 2024-12-31 | $7.21M DEF 14A · filed 2026-04-14 |
| 2023-12-31 | $14.20M DEF 14A · filed 2026-04-14 |
| 2022-12-31 | -$4.48M DEF 14A · filed 2026-04-14 |
| 2021-12-31 | $29.79M DEF 14A · filed 2026-04-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |